Iskra Pusic, MD, Washington University in St. Louis, St. Louis, MO, discusses recent advances in the management of acute graft-versus-host disease (GvHD) and their implications for clinical practice. Dr Pusic highlights the recent approval of ruxolitinib for the management of acute GvHD and talks on how, with biomarker development, it is now possible to effectively assess the risk of developing GvHD, the risk of relapse, and predict the response to therapy. Dr Pusic comments on several ongoing trials investigating novel agents to treat acute GvHD, and comments on the importance of conducting trials focusing on preventing severe forms of GvHD. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

свернуть